CEO AilseVax: Developing cancer antigen drug discovery platform AltRNA8V and new adjuvant cancer therapies. private account views are my own
Belfast
Joined March 2014
- Tweets8.1K
- Following521
- Followers588
- Likes34.8K
Paul K retweeted
The 2026 Fierce 15 is here.
Meet the 15 private biotech companies our editors selected as some of the most promising in the industry. fiercebiotech.com/biotech/in… #Fierce15
Paul K retweeted
Truth from my Euro colleagues. We are not HQ’d there but have massive operations in Europe. Unfortunately, short sighted policies are driving us all to the exit doors. When I joined this industry 30 years ago this was a European led industry, today Research, Clinical Development and Manufacturing are all shrinking in relative terms..Moving mostly to the US and increasing to China. The fix isn’t complicated but it is seemingly hard for them - improve IP, speed up the regulatory environment, value and pay for innovation - and the window is rapidly closing.⏱️
reuters.com/legal/litigation…
Paul K retweeted
INCREDIBLE!
Washington Post journalist Hannah Natanson who had Trump’s FBI raid her home and take her phones and laptops, just won the Pulitzer Prize with the Washington Post.
Congrats!!
Paul K retweeted
Here is the Sun's pitifully small apology for its lie about benefits tourism - a lie that was accepted as truth by millions and helped deliver Brexit.
These lies are perverting our democracy. At a minimum, apologies should be published in the same location and size as the lie.
Paul K retweeted
This is HUGE
Can you help get this story out there??
Let's RT this 10,000 times!!!
NEW: Police knew a Kremlin spy ring recruited former leader of Reform Wales at least 3 years ago.
So why was Nathan Gill not charged till Feb this year?
Pls read part 2 of @thenerve_news special investigation into Nathan Gill. And please share!
1/
Paul K retweeted
We are delighted to announce a further £1.2 million of Innovate UK Launchpad funding to be released this month for businesses with ambition for growth and working in life and health sciences.
Find out more lnkd.in/eryn9336HIRANI & register your interest lnkd.in/eewfjsGN
Paul K retweeted
I think that @BBCNews, @SkyNews @ITVNewsPolitics and @Channel4News should all be reporting on Reform UK and Russian bribery.
RT if you agree!!
Why are the media ignoring such a blatant story?!
Paul K retweeted
I love the idea that she ‘checked’
You’re unable to view this Post because this account owner limits who can view their Posts. Learn more
Paul K retweeted
Cancer cachexia = an underdiagnosed, lethal syndrome.
· Affects up to 80% in pancreatic CA, 40% in lung.
· It’s not just weight loss—think systemic inflammation, altered metabolism, fat/muscle wasting.
· GDF-15, IL-6, activin A are key molecular drivers.
· A major unmet need in cancer patients
aacrjournals.org/cancerdisco…
Paul K retweeted
1/Here’s an excellent Financial Times article which accurately describes the problematic situation which many big Pharma companies such as $PFE $JNJ $BMY $ABBV $LLY $MRK $SNY and others are now facing - the upcoming patent cliff scenario. With IP rights which are about to expire in 2027-2028, big Pharma companies face a huge pressure on both their pipeline and their future revenue streams and here is how they intend to address this burning issue. $XBI 🧵👇
ALT Here’s a fascinating FT article which accurately describes the problematic situation which many big Pharma companies such as Pfizer, Johnson and Johnson Eli Lilly and others are now facing - the upcoming patent cliff scenario. With IP rights which are about to expire in 2027-2028, big Pharma companies face a huge pressure on both their pipeline and their future revenue streams and here is how they intend to address this burning issue.
Paul K retweeted
🧬 The Future of Antibody-Drug Conjugates (ADCs): 2025-2035
ADCs are hitting their stride.
From 15 approvals today to 40+ by 2035, they’re becoming one of the most powerful therapeutic platforms in biotech.
Here’s a year-by-year breakdown of what’s coming next 👇🏼
Paul K retweeted
Great to see the UK Government’s Life Sciences Sector Plan published, which looks to harness UK science and innovation, strengthen the NHS and drive long-term economic growth.
The UK Government’s ambition is that the UK will be the leading life sciences economy in Europe by 2030 and the third most important globally by 2035.
In particular, it was great to read of the UK Government’s particular focus on innovative medicines that reduce hospital admissions. See this in Action 28: Reduce friction in the system to optimise access and uptake of new #drugs – on page 38.
POLB 001, our preventative therapy targets cancer immunotherapy-induced CRS and can potentially reduce or remove the need for patient hospitalisation when receiving cancer immunotherapy treatment.
Full report published here:
gov.uk/government/publicatio…
#POLB #Healthcare #10yearPlan #LifeSciences #UK #NHS #Hospitalisations #CRS #Treatments
Paul K retweeted
17 million people just lost health care.
18 million kids just lost school meals.
3 million Americans just lost food assistance.
And $3.5 trillion was added to the deficit.
All for a tax cut for Trump’s billionaire donors.
The ultimate betrayal.
Paul K retweeted
CITY OF DERRY WALK - NOW ON A SUNDAY
Join us on Sunday 14th September for a beautiful walk along the banks of the river Foyle. The perfect opportunity to get together with family and friend to help us mark blood cancer awareness month.
llni.co.uk/event/city-of-der…
#BCAM2025
Paul K retweeted
Great to see such progress, but we have a lot of work to do for patients with lung, oesphageal, liver and pancreatic cancers.
Reflects the absolute importance of #ClinicalTrial in improving outcomes
@cancertrials_ie @CancerInstIRE @IRROGTrials @IrishCancerSoc
Great graphics and global overview on cancer prevalence and therapeutic improvements in this article. Overall cancer survival rates have moved from 50% end of the 70s to 67% in 2013.
ourworldindata.org/cancer
